(Rac)-Cemsidomide

Cat. No.: HY-144841A

CAS No.: 2504233-68-3

Molecular Formula: $C_{28}H_{27}N_3O_4$

Molecular Weight: 469.53

Target: Others

Pathway: Others

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 62.5 mg/mL (133.11 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.1298 mL	10.6489 mL	21.2979 mL
	5 mM	0.4260 mL	2.1298 mL	4.2596 mL
	10 mM	0.2130 mL	1.0649 mL	2.1298 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (4.43 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

(Rac)-Cemsidomide ((Rac)-CFT7455) is a zinc finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) degrader, acting via the ubiquitin proteasome pathway, with a GI_{50} of 0.05 nM for NCIH929.1 cells. (Rac)-Cemsidomide is the racemic isomer of Cemsidomide (HY-144841A) which is a IKZF1/IKZF3 degrader with anticancer activity[1][2].

IC_{50} & Target

Ikaros, Aiolos[1]

REFERENCES

[1]. David Proia et al. Advantageous therapies for disorders mediated by ikaros or aiolos. WO2022032132A1 (compound 5)

[2]. James A. Henderson, et al. Abstract LB007: CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models. Cancer Res (2021) 81 (13_Supplement): LB007.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA